WuXi AppTec at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

WuXi AppTec brings 2 presentations to ENA 2026 in Barcelona, and exhibits at Booth 9. Its posters centre on drug resistance models for testing next-generation treatments. They include a TOP1-mutant cancer model for evaluating new antibody-drug conjugates and the different ways KRAS-mutant cancers acquire resistance to the RAS(ON) multi-selective inhibitor daraxonrasib.

Organization	ENA 2026 Attendance
WuXi AppTec Shanghai, China
wuxiapptec.com CROs & CDMOsExhibitor Contract research, development and manufacturing organization offering drug discovery, in vivo pharmacology, testing and manufacturing services.	Booth Exhibiting at Booth 9 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Breaking through ADC resistance: generating TOP1 mutation cancer model and evaluating next generation ADCs ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer Targeted agents

Organization

ENA 2026 Attendance

WuXi AppTec

Shanghai, China

wuxiapptec.com

CROs & CDMOsExhibitor

Contract research, development and manufacturing organization offering drug discovery, in vivo pharmacology, testing and manufacturing services.

Booth

Exhibiting at Booth 9

Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm